An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue.
Katz JR., Mohamed-Ali V., Wood PJ., Yudkin JS., Coppack SW.
Laboratory Study with a reported sample of 34, published in Clin Endocrinol (Oxf) (1999) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Clin Endocrinol (Oxf) (1999)
- Country
- England
- Reported sample size
- 34
- Source database
- PubMed
- PMID
- 10341857
- DOI
- 10.1046/j.1365-2265.1999.00598.x
Abstract (original English)
Previous in vitro studies have demonstrated significant 11-beta hydroxysteroid dehydrogenase (11 beta-HSD) oxo-reductase activity in visceral, but not subcutaneous adipose stromal cells. We have conducted an in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. We measured arteriovenous (A-V) differences in serum cortisol and cortisone across subcutaneous abdominal adipose tissue and forearm muscle in a heterogeneous group of subjects. We studied 34 subjects (male:female = 12:22), age median (interquartile range) 45 (19-65) years, body mass index 32.7 (20.4-77.1) kg m-2, total body fat 34.4 (5.6-119.1) kg. Serum cortisol and cortisone were measured in serum samples from a radial artery, superficial epigastric vein and deep forearm vein. Abdominal adipose and forearm blood flow rates were measured by 133Xenon washout and plethysmography, respectively. For cortisone, there was significant (P < 0.001) clearance by adipose tissue, with an A-V difference of 4 (1-7) nmol/l. For cortisol there was a trend for arterial concentrations (203 (142-292) nmol/l) to be lower than venous (225 (152-263) nmol/l), but this was not significant. The adipose tissue cortisone clearance rate correlated with total body fat (r = 0.35, P = 0.05). We have demonstrated 11 beta-HSD oxo-reductase activity in subcutaneous abdominal adipose tissue, which may be increased in
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.